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Abstract
A vaccine to prevent infections from the emerging Neisseria meningitidis X (MenX) is becoming an urgent issue. Recently MenX
capsular polysaccharide (CPS) fragments conjugated to CRM197 as carrier protein have been confirmed at preclinical stage as
promising candidates for vaccine development. However, more insights about the minimal epitope required for the immunological
activity of MenX CPS are needed. We report herein the chemical conjugation of fully synthetic MenX CPS oligomers (monomer,
dimer, and trimer) to CRM197. Moreover, improvements in some crucial steps leading to the synthesis of MenX CPS fragments are
described. Following immunization with the obtained neoglycoconjugates, the conjugated trimer was demonstrated as the minimal
fragment possessing immunogenic activity, even though significantly lower than a pentadecamer obtained from the native polymer
and conjugated to the same protein. This finding suggests that oligomers longer than three repeating units are possibly needed to
mimic the activity of the native polysaccharide.
Introduction
Neisseria meningitidis is an encapsulated, aerobic gram-nega-
tive diplococcus which causes significant morbidity and
mortality in newborns, children and young adults worldwide
through meningitis and/or septicemia. Although sporadic cases
occur in Europe and North America, major meningitis
epidemics have been recorded in Africa, in an area termed “the
meningitis belt”, extending from Senegal to Ethiopia and
including 21 countries with a population of over 300 million
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people. According to the chemical composition of the bacterial
capsular polysaccharide (CPS) [1], 13 serogroups of N. menin-
gitidis have been so far defined. Until recently only five of them
(A, B, C, Y, W135) were associated with significant patho-
genic potential [2,3]. In particular serogroup A (MenA), that
caused significant meningitis outbreaks in industrialised coun-
tries until the 1970s [4], is currently a major responsible for
epidemics in the African meningitis belt. Additionally, since
2002 serogroup W135 has also been considered a major threat.
In the past 20 years sporadic cases or clusters of meningitis due
to other N. meningitidis serogroups have emerged. While the
impact of infections caused by serogroup X of N. meningitidis
(MenX) was initially considered negligible, in the last decade
incidence rates and disease characteristics very similar to other
virulent meningococcal isolates have been reported. As a matter
of fact, the meningitis cases ascribed to MenX do not present
any clinical or epidemiological differences to those due to
serogroup A. Most cases (93%) were recorded during the dry
season, with a mean age of the patients of 9.2 years and a
fatality rate of 11.9% [5]. MenX was first described in the
1960s [6], when it was found to cause a few cases of invasive
disease across North America, Europe, Asia and Africa [7]. The
first case of MenX disease in Africa was documented in 1974
and, since then, several sporadic cases have been observed in
other African countries [8]. In 2006, the occurrence in Niger of
MenX related meningitis infections with unprecedented inci-
dence led the World Health Organization (WHO) to consider
MenX as a substantial threat [9]. However, it was only in 2010
that, following a very large MenX outbreak in Burkina Faso, the
WHO-Inter-country Support Team (WHO-IST) weekly
bulletins on meningitis started to specifically document MenX
epidemics [10]. Interestingly, while MenA incidence decreased
in most meningitis belt countries following the introduction in
2010 of a monovalent MenA conjugate vaccine (MenAfriVac)
[11,12], an increase in MenX cases has been observed. Recently
a study revealed that in Burkina Faso the levels of MenX
carriage after the introduction of the MenA conjugate vaccine
are significantly higher than they were before the vaccine intro-
duction [13]. This could suggest a serotype replacement due to
mass vaccination with MenAfriVac, although this event should
be considered unlikely on the basis of previous experiences
with the introduction of the MenC conjugate vaccine [14].
Undoubtedly the recent increase of MenX infections has led to
take in consideration this emerging serogroup for the develop-
ment of new meningococcal vaccines [15,16]. Recently it has
been reported that coupling long chain oligosaccharides from
MenX CPS to the nontoxic mutant of diphtheria toxin Cross-
Reacting Material 197 (CRM197), a protein widely used in
manufactured vaccines,[17] provides a potent candidate for
the development of a glycoconjugate vaccine against this
serogroup [18].
MenX CPS is a homopolymer of (1→4)-linked 2-acetamido-2-
deoxy-α-D-glucopyranosyl phosphate residues (Figure 1). The
synthesis of the repeating unit was first reported in 1974 [19],
and more recently an improved protocol for larger scale prepar-
ation of the monomer as analytical tool has been also described
[20]. Notably, the minimal CPS portion which can confer
protection against meningococcal infections is still unknown.
Figure 1: Structures of the repeating unit of MenX CPS and synthetic
oligomers 1–3.
Over the recent years, advances in the synthesis of complex
glycans are rendering accessible a variety of carbohydrate anti-
gens with well-defined chemical structure and devoid of bacte-
rial contaminations which could derive from purification of bio-
logical materials [21-24]. This could be a crucial feature to
improve batch-to-batch consistency in vaccine manufacturing
and to confer a better safety profile.
Some of us have recently achieved the first synthesis of short-
chain MenX CPS oligomers (compounds 1–3, Figure 1)
provided with a phosphodiester-linked aminopropyl spacer suit-
able for their conjugation to a carrier protein [25].
These synthetic molecules are valuable tools to obtain informa-
tion on the minimal structural requirements for the immunolog-
ical activity of MenX CPS and for evaluation as vaccine candi-
dates. In the present work we report the preparation and in vivo
immunological evaluation of neo-glycoconjugates from the
fragments 1–3. In this context, we describe the significant
improvements recently achieved in some crucial steps of our
previously reported synthesis [25] that will render more expedi-
tious the preparation of this type of oligomers.
The synthetic oligomers 1–3 were conjugated to the surface
abundant lysine residues of the carrier protein CRM197 by
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means of the di(N-succinimidyl) adipate (SIDEA) linker. We
have already shown that this spacer, which is used in commer-
cial anti-meningococcal vaccines for the feature of being
immuno-silent, can be efficiently utilized for the conjugation of
short synthetic antigens bearing an amino spacer [26,27]. The
synthesized CRM197 glycoconjugates were first tested for their
capability of eliciting anti MenX CPS antibodies in mice. The
functional activity of the generated antibodies was then assessed
by the in vitro bactericidal assay recently developed for the
evaluation of MenX CPS conjugates [18].
Results and Discussion
Improvements in α-H-phosphonate synthesis
Our previous synthesis of oligomers 1–3 featured the use of
2-azido-2-deoxy glucopyranosyl building blocks and their
corresponding glycosyl hydrogenphosphonates (H-phospho-
nates) intermediates for the installation of the phosphodiester
linkages [28].
We were confident that the use of the non-participating and
electron-withdrawing azido group could strongly enhance the
stability of the anomeric phosphodiester linkages. However, we
experienced a dramatic drop of the overall yield during the
conversion of the azido groups in acetamides on protected
glycosyl phosphosaccharide intermediates [25].
We therefore sought to design a different strategy based on
GlcNAc instead of azido glucose building blocks, where the
azide reduction is rather performed at an early stage of the syn-
thetic route than on valuable advanced intermediates. Accord-
ingly, the azide reduction with NiCl2/NaBH4 protocol [29]
occurred smoothly on the previously described [25] silyl glyco-
side 4, and after standard N-acetylation furnished acetamide 5
in high yield (Scheme 1).
Scheme 1: Reagents and conditions: a) NiCl2/NaBH4, MeOH; b)
Ac2O, 86% over 2 steps; c) TBAF, THF, −40 °C to rt, 81%; d) sali-
cylchlorophosphite, pyridine, then 1M triethylammonium hydrogencar-
bonate buffer solution (TEAB): Batch 62% yield; MRT 76% yield. TDS:
Thexyldimethylsilyl.
On the other hand, the same reaction carried out on protected
glycosyl phosphosaccharides afforded the corresponding
acetamides in 25–35% yield [25]. Interestingly, when com-
pound 5 was subjected to 1-O-desilylation with tetrabutylam-
monium fluoride in THF at –40 °C, we obtained exclusively the
α-hemiacetal 6 in 81% yield (Scheme 1). The formation of the α
anomer was confirmed by the doublet of H-1 at 5.23 ppm in the
1H NMR spectrum with the typical value of 1J1,2 = 3.5 Hz, and
the appearance of the C-1 signal at 92.0 ppm in the 13C NMR
spectrum (see Supporting Information File 1).
Most importantly, when the hemiacetal 6 was treated with sali-
cylchlorophosphite in pyridine at room temperature the α-H-
phosphonate 7 was obtained as a single anomer in only 2 h in
62% yield. We reasoned that the occurrence of an intramolec-
ular hydrogen bond involving the acetamido group could be the
main responsible for the high selectivity observed in the forma-
tion of compound 6 and, consequently, for the attainment of the
pure α-H-phosphonate 7. Indeed, the desilylation of the 2-azido
counterpart of intermediate 5 provided a mixture of anomers.
On the other hand, the same reaction carried out on a
2-acetamido derivative very similar to 5 but protected as a 4,6-
O-benzylidene acetal also led to an anomeric mixture,
suggesting that conformational factors might be also involved.
In addition, the treatment of this mixture with sali-
cylchlorophosphite produced a mixture of anomeric H-phospho-
nates, indicating that no equilibration of the anomers occurs
during this reaction. We, therefore, ascribed the high stereose-
lectivity observed in the formation of compound 7 to the
stability of compound 6, whose configuration is preserved
during the reaction with salicylchlorophosphite. This finding
introduced a great improvement in our reported synthesis of
MenX CPS oligomers, since in the previous protocol extremely
long reaction times (6–7 days) were needed for the exclusive
formation of the most thermodynamically stable α-H-phospho-
nate by equilibration in the presence of H3PO3 of the initially
formed mixture of anomeric H-phosphonates [25]. An addition-
al improvement in α-H-phosphonate 7 formation was achieved
by carrying out the reaction under microfluidic conditions. The
Micro Reactor Technology (MRT) is gaining increasing atten-
tion for drug discovery. Some of its various possible advan-
tages when compared to more conventional approaches are im-
proved safety characteristics, enhanced rates of heat and mass
transfer, simplicity and robustness in scale-up and easiness in
handling the instrumentation [30-33]. For the synthesis of com-
pound 7, two distinct solutions containing the hemiacetal 6 in
pyridine and salicylchlorophosphite in CH3CN, respectively,
were pumped in a 100 μL glass microreactor. The device was
completed by a reservoir connected to the outlet of the microre-
actor, refilled with a solution of triethylammonium bicarbonate
buffer (TEAB) 1.0 M to stabilize the H-phosphonate product.
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Scheme 2: Reagents and conditions: a) PivCl in pyridine, then I2 in 19:1 pyridine/H2O, then 1 M TEAB (45%); b) NaOMe, MeOH; c) H2, Pd/C, MeOH/
H2O, then H2O, Dowex 50W X8 resin (H+ form), then Dowex 50W X8 resin (Na+ form) (96% over two steps).
Setting the residence time to 3 min, 46 mg of the α-H-phospho-
nate 7 were obtained in 0.5 h at higher isolated yield (76%) and
purity than batch reaction. Based on the maximum volume of
the syringes employed in our continuous-flow system (5 mL,
see Supporting Information File 1), we can estimate that a
production rate of 2.2 g/day would be achievable. To the best of
our knowledge, this is the first example of the synthesis of
glycosyl H-phosphonates using the continuous-flow MRT [30-
33].
The occurrence of the H-phosphonate 7 was ascertained by a
signal at 1.87 ppm in the 31P NMR, and the presence in the
1H NMR of the diagnostic doublet at 6.93 ppm with the charac-
teristic value of 1JH,P = 631.8 Hz, typical of this class of com-
pounds [34]. The α-configuration of the anomeric carbon
was confirmed by a doublet of doublet at 5.53 ppm, with 1J1,2 =
3.2 Hz, 1J1,P = 8.4 Hz (see Supporting Information File 1).
The benefit of the easy availability of the α-hemiacetal 6 was
illustrated by the improved synthesis of the spacer-linked MenX
monomer 1 (Scheme 2). The PivCl-mediated coupling of 6 with
compound 8 [35,36] provided the glycosylphosphodiester 9 as a
pure α-anomer, demonstrating the configurational stability of
the hemiacetal under these reaction conditions. Compound 9
was subjected to Zemplén transesterification with NaOMe in
methanol to afford alcohol 10, and the hydrogenolytic removal
of the remaining protective groups furnished the spacer-linked
monomer 1 in excellent yield (Scheme 2).
Chemical synthesis of neo-glycoconjugates
Fragments 1–3, obtained as previously reported [25], were
employed as follows for the synthesis of the corresponding
CRM197 conjugates. First the oligomers 1–3 were activated by
reaction with an excess of SIDEA in the presence of triethy-
lamine in DMSO (Scheme 3). The products were purified by
precipitation from ethyl acetate, and after freeze-drying the half
esters 11–13 were obtained at 49–65% yield. Of note, while we
have utilized a similar procedure for fast and efficient insertion
of the monoester of the immunosilent adipate linker onto a
number of different length glycans [26,27], lower yields were
attained in the present case. This can be explained with the
higher solubility in organic solvents of the short structures
11–13 employed in the present study in comparison to other
reported oligosaccharides [26,27], which did not allow
complete precipitation of the activated oligomers. To increase
the yield of this step, compounds 11–13 were recovered from
the dimethylsulfoxide–ethyl acetate mixture by evaporation of
ethyl acetate and addition of fresh ethyl acetate at 0 °C. The
newly precipitated activated carbohydrates were freeze-dried
and coupled to the protein. In this way, almost quantitative
recovery of the activated sugars 11–13 was achieved.
Active esters 11–13 were then coupled with the amino groups
of the protein in sodium phosphate buffer (100 mM NaPi,
pH 7.2) at room temperature for 24 h (Scheme 3).
The glycoconjugates 14–16 were purified from the excess of
unconjugated carbohydrate by precipitation with ammonium
sulfate and reconstitution in 10 mM NaPi pH 7.2. The occur-
rence of conjugation was assessed by SDS-PAGE (sodium
dodecyl sulfate polyacrylamide gel electrophoresis) and
MALDI–TOF mass spectrometry (see Supporting Information
File 1). The latter analytical technique enabled determination of
the saccharide/protein molar ratio (saccharide loading). The
characteristics of the prepared glycoconjugates are summarized
in Table 1.
A moderate loading (5–7 sugars/protein) was obtained in com-
pounds 14–16 in respect to conjugates prepared by the same
conjugation chemistry and different carbohydrate structures
[26,27]. However, it needs to be taken in consideration that this
loading is comparable to that achieved in the preparation of
anti-meningococcal vaccines commercially available [37].
Furthermore, a number of 2.5 and 1.7–4.1 sugar moieties were
incorporated in our positive control 17 and in the MenX CPS
glycoconjugates recently reported to induce protective anti-
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Scheme 3: Reagents and conditions: a) SIDEA, Et3N, DMSO: 11 (64%), 12 (49%), 13 (51%); b) CRM197, 100 mM NaPi pH 7.2.
Table 1: Characteristics of the synthesized glycoconjugates.
Glyco conjugate Activated ester/protein
(mol/mol)a
Saccharide conjugation
(mol/mol)b
MW (Da) Loading efficiency %a
14 75:1 7 61523 9
15 75:1 4.5 61731 6
16 75:1 4.7 63256 6
MenXDP15CRM197 17 13:1 2.5 n.d. 19
aMol of activated glycan: mol of protein used in the conjugation reaction. bSugar:protein molar ratio determined by MALDI–TOF MS for 14–16, and by
HPAEC-PAD analysis for MenXDP15-CRM197 conjugate 17.
bodies, respectively [18]. Thus, we deemed the loading of
glycoconjugates 14–16 sufficient to determine in vivo their
capability of eliciting anti-MenX CPS antibodies.
Immunological evaluation of CRM197 conju-
gates
To evaluate the immunogenicity of the synthesized glycoconju-
gates, groups of 8 BALB/c mice were immunized with three
doses (two weeks apart) of 0.3 μg on saccharide base of the
neo-glycoconjugates. The conjugated trimer 16 was also
injected at 1 μg carbohydrate base dose to evaluate the effect of
dose variation. The conjugates were formulated with aluminum
phosphate, an adjuvant commonly used for vaccines in the
market or in preclinical development [38]. As a control, the
CRM197 conjugate with MenX fragments having an average
degree of polymerization (avDP) of 15 (MenXDP15-CRM
conjugate, compound 17) was used at the saccharide base doses
of 0.3 and 1 μg, respectively.
As shown in Figure 2, while the CRM197 conjugates of the
monomer 1 and the dimer 2 did not induce polysaccharide
specific IgG titers, the conjugated trimer 3 elicited anti-MenX
CPS IgG titers, with no statistical difference (p 0.05) at the
doses of 0.3 and 1 μg, respectively.
The MenXDP15 conjugate 17 also induced anti-MenX CPS
antibodies that were comparable each other at the two
different doses (p 0.05). However, the IgG levels induced by the
trimer conjugate 16 at both 0.3 and 1 μg dose were signifi-
cantly lower than those elicited by the conjugate 17 adminis-
tered at the corresponding doses (p 0.0009 and 0.039 for 0.3 and
1 μg dose, respectively). Importantly, all the conjugates induced
very low anti-MenX IgM titers, but the trimer 3 and the
MenXDP15 antigens conjugated to the carrier enabled
switching from IgM to IgG, which is characteristic of the T cell
dependent response (for IgM levels see Supporting Information
File 1).
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Figure 3: A) IgG levels detected at OD = 1 in individual post 3 sera of BALB/c mice immunization at 0.3 μg saccharide dose of antigen. A) Sera from
conjugates 14, 15 and 16 were tested against the monomer-, dimer- and trimer-HSA conjugate, respectively, presenting different linker and protein
(see Supporting Information File 1). B) Comparison of anti trimer-HSA antibody levels in sera from conjugates 14–17. Each point represents indi-
vidual mouse sera; horizontal bars indicate geometric mean titers (GMT) of each group with 95% statistical confidence intervals indicated by upper
and lower bars.
Figure 2: IgG levels detected at OD = 1 in individual post 3 sera (sera
collected two weeks after the third immunization) of BALB/c mice
immunization at 0.3 or 1 μg saccharide dose of antigen against MenX
CPS as coating plate. Each dot represents individual mouse sera; hori-
zontal bars indicate geometric mean titers (GMT) of each group with
95% statistical confidence intervals indicated by upper and lower bars.
Since the trimer 3, among the set of conjugated synthetic
oligomers, was the only structure capable of inducing IgG anti-
bodies against the MenX CPS, we interrogated whether the sera
from the three conjugated synthetic fragments were capable to
recognize their own structures. To answer this question, conju-
gates with HSA were prepared with a similar protocol to that
used for the formation of the CRM197 conjugates, except that a
bis-succinimidyl ester penta-ethylene glycol (BS(PEG)5) linker
was used to rule out the interference of the spacer (details are
reported in Supporting Information File 1). ELISA analysis
using HSA conjugates as coating reagent demonstrated that the
conjugated monomer 1 and the dimer 2 at the present dose
elicited extremely low levels of antibodies against themselves
and were, therefore, scarcely antigenic. By contrast, the trimer 3
was the only fragment which evoked a robust antibody produc-
tion against its own structure (Figure 3A).
Surprisingly, when the trimer-HSA conjugate was used as
coating reagent for the ELISA analysis (Figure 3B), sera
elicited by the monomer 1 exhibited low anti-trimer antibodies,
whereas sera induced by the conjugated dimer 2 and the trimer
3 possessed comparable levels of antibodies against the tri-
saccharide structure. The IgG levels raised by the trimer-
CRM197 conjugate 16 were in turn significantly lower
(p 0.0005) than those elicited by the MenXDP15-CRM197
conjugate 17, where the trisaccharide is repeated multiple times.
We hypothesize that the improved binding of antibodies
induced by 14 and, primarily, by 15 to the coated trisaccharide
conjugate rather than to 1- and 2-HSA conjugates, respectively,
might be the result of a better exposition of monosaccharide and
disaccharide MenX units in the context of the trimer-HSA
Beilstein J. Org. Chem. 2014, 10, 2367–2376.
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molecule, due presumably to conformational or spatial factors.
However, this peculiar recognition was not observed when the
native MenX CPS, which is the structure that best resembles the
bacterial sugar surface and consequently of major interest for
vaccine development, was used as coating reagent (Figure 2).
Together, these evidences indicated that the trimer is the
minimal antigenic portion of the polymer which is also capable
of inducing antibodies recognizing epitopes of MenX CPS.
Next, the functionality of the induced antibodies was assessed
by measuring the rabbit complement-mediated lysis of N.
meningitidis [39]. This in vitro bactericidal assay is typically
used to predict the effectiveness of anti-meningococcal vaccines
[40,41]. Rabbit complement serum bactericidal assay (rSBA)
titers were determined using pooled sera from mice immunized
with the conjugated monomer 14, dimer 15, trimer 16 and
MenXDP15 17. As it can be seen from Table 2, rSBA titers
showed a trend similar to the measured ELISA IgG levels.
Table 2: rSBA titers of sera from immunized mice.
Sample Antigen
dose
Adjuvant rSBA
titer
PBS - Al phosphate <16
14 0.3 µg Al phosphate <16
15 0.3 µg Al phosphate <16
16 0.3 µg Al phosphate 512
16 1 µg Al phosphate 512
MenXDP15-CRM197 17 0.3 µg Al phosphate 8192
MenXDP15-CRM197 17 1 µg Al phosphate 8192
Only pooled sera from mice immunized with the conjugated
trimer 16 demonstrated to be functional, whereas compounds 14
and 15 did not exhibit any bactericidal activity. However, the
rSBA titers of the trimer at 0.3 and 1 μg saccharide base doses
were significantly lower (<10 fold in terms of titer) than
MenXDP15-CRM197 conjugate 17 at the corresponding doses
(512 and 8192, respectively).
To sum up, following conjugation to the carrier protein the
chain of three repeating units constitutes the minimal antigenic
structure of MenX polysaccharide, but its immunogenicity
towards the native polysaccharide is lower than a medium size
MenX CPS fragment (avDP 15) both in terms of IgG levels and
functionality of the induced antibodies.
Conclusion
Serogroup X N. meningitidis is dramatically emerging among
the causative agents of meningitis, particularly in Africa. Simi-
larly to other serogroups, polysaccharide-based conjugates have
been recently proposed as target molecules for the development
of a vaccine with a broader coverage. We have undertaken the
preparation of neo-glycoconjugates from fully synthetic MenX
fragments in order to gain structural insights about minimal
epitopes of this polysaccharide, and investigate the possibility
of using synthetic pure and well-defined carbohydrates for the
development of a glycoconjugate vaccine.
While, at the present dose and carbohydrate loading, conju-
gates of the synthetic MenX PS monomer and dimer with
CRM197 were poorly antigenic, the conjugated trimer resulted
in the minimal structure eliciting antibodies that can recognize
both itself and epitopes of the native polysaccharide. Further-
more, these antibodies possess anti-meningococcal bactericidal
activity towards serogroup X, although in less extent than a
medium size native MenX CPS fragment (avDP 15).
This finding suggests that oligomers longer than three repeating
units might be required to fully mimic the polysaccharide
activity, and paves the ground for a deeper understanding of the
structural requirements needed to develop a conjugate vaccine
based on well-defined oligosaccharides attained by chemical
synthesis. The preparation of these longer chain MenX frag-
ments, based on the synthetic improvements and also the bene-
fits of the continuous-flow microreactor technology herein
described, is currently ongoing in our laboratory and it will be
reported in due course. Besides the length of the carbohydrate
haptens, the saccharide loading onto the protein is another key
parameter which has been shown to deeply affect the immuno-
genicity of glycoconjugate vaccines [42,43]. In the present
preliminary study, glycoconjugates with moderate loading were
compared. It has been reported for other bacterial systems that
the immunogenicity of short oligosaccharides can be enhanced
by increasing the number of glycan antigens incorporated onto
the carrier protein. The utilization of other conjugation
chemistries enabling the achievement of higher carbohydrate
loadings and the study of the effect of different glycan–protein
ratios on glycoconjugates prepared from these short synthetic
MenX fragments also deserve further exploration.
Experimental
General procedure for conjugation of fragments 1–3. This
procedure is similar to that reported in reference [27]. The
glycan (10 μmol) dissolved in DMSO (250 μL) containing
triethylamine (25 equiv), was slowly dropped into a mixture of
bis(N-succinimidyl) adipate (10 equiv) in DMSO (250 μL).
After 3 hours under vigorous stirring, the activated oligosaccha-
ride was purified by precipitation of the reaction mixture in
nine volumes (9 mL) of ethyl acetate. The pellet obtained by
subsequent centrifugation was washed with ethyl acetate
(10 times × 3 mL), and freeze dried. After spectrophotometric
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determination of active ester groups, the pellet was incubated
overnight with the protein in 100 mM NaPi pH 7.2.
The glycoconjugate was washed on a 30 kDa Amicon
centrifugal filter with 10 mM NaPi pH 7 (8 × 100 μL), and
subsequently reconstituted with 10 mM NaPi pH 7. Yields
(recovered glycoprotein as determined by microBCA, Pierce
Thermo): 85–95%. Loading of glycoconjugate was determined
by matrix-assisted laser desorption ionization time-of-flight
mass spectrometry (MALDI–TOF MS; UltraFlex III
MALDI–TOF/TOF instrument, Bruker Daltonics) in linear
mode and with positive ion detection. The samples for analysis
were prepared by mixing 2.5 μL of product and 2.5 μL of sinap-
inic acid matrix (Bruker Daltonics); 2.5 μL of each mixture was
deposited on a samples plate, dried at room temperature for
10 min, and subjected to the spectrometer.
For SDS page analysis, the samples (5 μg) were elec-
trophoresed on a 7% TrisAcetate gel or 4–12% Bis-Tris gel
(NuPage, Invitrogen) and stained with Coomassie blue.
Immunization of mice. Animal experimental guidelines set
forth by the Novartis Animal Care Department were followed in
the conduct of all animal studies. For the formulation of the
vaccines, to a volume of glycoconjugate corresponding to
0.3 μg or 1 μg/dose) aluminium phosphate (100 μl of a solution
1.2 mg/mL, 120 μg/dose) was added. The final volume of the
formulation was diluted to 200 μL/dose by addition of PBS
pH 7.2 buffer. An injection volume of 200 μL per mouse was
used. MenX vaccines were administered to mice in 0.3 or 1 μg
per dose based on saccharide content. As in [27] mice were
immunized subcutaneously at day 1, 14 and 28. Bleedings were
performed at day 0 (pre immune), day 28 (post 2) and day 42
(post 3). Control groups received PBS with adjuvant.
ELISA analysis. The antibody response induced by the glyco-
conjugates against the MenX polysaccharide and the HSA
conjugates (see Supporting Information File 1) were measured
by ELISA. Similarly as described in [27], plates were coated
with the polysaccharide by adding 100 μL/well of a 5 μg/mL
polysaccharide solution in pH 8.2 PBS buffer, and with the
HSA conjugates adding 100 μL/well of a 2 μg/mL in term of
protein solution in pH 7.2 PBS buffer, followed by incubation
overnight at 4 °C. Coating solutions were removed from the
plates by washing each well three times with PBS buffer
containing 0.05% of Tween 20 (Sigma) (TPBS). A blocking
step was performed by adding 100 μL of BSA solution at 3% in
TPBS and incubating the plates 1 h at 37 °C. Blocking solution
was removed from the plates by washing three times per well
with TPBS. 200 μL of pre-diluted serum (1:25 for pre immune,
1:200 for a reference serum, 1:50–1:100 for test sera) was
added to the first well of each column of the plate, while 100 μL
of TPBS was dispensed into the remaining wells. Eight two-fold
serial dilutions along each column were then performed by
transferring from well to well 100 μL of sera solutions. After
primary Abs dilution, plates were incubated for 2 h at 37 °C.
After three washings with TPBS, 100 μL TPBS solutions of
secondary antibody alkaline phosphatases conjugates (anti-
mouse IgG 1:10000, anti-mouse IgM 1:5000 Sigma-Aldrich)
were added and the plates incubated 1 h at 37 °C. Three more
washes with TPBS were performed, when 100 μL/well of a
1 mg/mL of p-NPP (Sigma) in a 0.5 M diethanolamine buffer
pH 9.6 were added. After 30 min of incubation at room
temperature, plates were read at 405 nm using a Biorad plate
reader. Raw data acquisition was performed by Microplate
Manager Software (Biorad). Sera titers were expressed as the
reciprocal of sera dilution corresponding to a cut-off OD = 1.
Each immunization group is represented as the geometrical
mean (GMT) of the single mouse titers. The statistical and
graphical analysis was performed by GraphPad 5.0 software.
Rabbit serum bactericidal assay (rSBA). The functionality of
antibodies induced by vaccine immunization was assessed by
measuring the complement-mediated lysis of N. meningitidis
with an in vitro bactericidal assay as described in the literature
[15,26]. Titers were expressed as the reciprocal serum dilution
resulting in 50% of bactericidal killing. Z9615 (MenX) was
used as reference strain.
Supporting Information
Supporting Information File 1
Experimental procedures for the synthesis of compounds 1,
5, 6, 7, 9, 19, copies of 1H NMR and 13C NMR spectra of
compounds 5–6 and 1H NMR, 13C NMR and 31P NMR
spectra of compounds 1, 7, 9.
[http://www.beilstein-journals.org/bjoc/content/
supplementary/1860-5397-10-247-S1.pdf]
Acknowledgements
We gratefully acknowledge MIUR-Italy (PRIN 2010-2011:
contract 2010JMAZML_003) for financial support. We are
grateful to Stefano Crotti for contributing to the MALDI TOF
analysis of glycoconjugates.
References
1. Yogev, R.; Tan, T. Hum. Vaccines 2011, 7, 828–837.
doi:10.4161/hv.7.8.16270
2. Morley, S. L.; Pollard, A. J. Vaccine 2001, 20, 666–687.
Beilstein J. Org. Chem. 2014, 10, 2367–2376.
2375
3. Nicolas, P.; Norheim, G.; Garnotel, E.; Djibo, S.; Caugant, D. A.
J. Clin. Microbiol. 2005, 43, 5129–5135.
doi:10.1128/JCM.43.10.5129-5135.2005
4. Stephens, D. S.; Greenwood, B.; Brandtzaeg, P. Lancet 2007, 369,
2196–2210. doi:10.1016/S0140-6736(07)61016-2
5. Djibo, S.; Nicolas, P.; Alonso, J.-M.; Djibo, A.; Couret, D.; Riou, J.-Y.;
Chippaux, J.-P. Trop. Med. Int. Health 2003, 8, 1118–1123.
doi:10.1046/j.1360-2276.2003.01126.x
6. Devine, L. F.; Rhode, S. L., III; Hagerman, C. R. Infect. Immun. 1972,
5, 48–54.
http://iai.asm.org/content/5/1/48
7. Gagneux, S.; Wirth, T.; Hodgson, A.; Ehrhard, I.; Morelli, G.; Kriz, P.;
Genton, B.; Smith, T.; Binka, F.; Pluschke, G.; Achtman, M.
Emerging Infect. Dis. 2002, 8, 462–466. doi:10.3201/eid0805.010227
8. Xie, O.; Pollard, A. J.; Mueller, J. E.; Norheim, G. Vaccine 2013, 31,
2852–2861. doi:10.1016/j.vaccine.2013.04.036
9. Boisier, P.; Nicolas, P.; Djibo, S.; Taha, M.-K.; Jeanne, I.;
Mainassara, H. B.; Tenebray, B.; Kairo, K. K.; Giorgini, D.;
Chanteau, S. Clin. Infect. Dis. 2007, 44, 657–663. doi:10.1086/511646
10. Delrieu, I.; Yaro, S.; Tamekloé, T. A.; Njanpop-Lafourcade, B.-M.;
Tall, H.; Jaillard, P.; Ouedraogo, M. S.; Badziklou, K.; Sanou, O.;
Drabo, A.; Gessner, B. D.; Kambou, J. L.; Mueller, J. E. PLoS One
2011, 6, e19513. doi:10.1371/journal.pone.0019513
11. Roberts, L. Science 2010, 330, 1466–1467.
doi:10.1126/science.330.6010.1466
12. Sow, S. O.; Okoko, B. J.; Diallo, A.; Viviani, S.; Borrow, R.; Carlone, G.;
Tapia, M.; Akinsola, A. K.; Arduin, P.; Findlow, H.; Elie, C.;
Haidara, F. C.; Adegbola, R. A.; Diop, D.; Parulekar, V.; Chaumont, J.;
Martellet, L.; Diallo, F.; Idoko, O. T.; Tang, Y.; Plikaytis, B. D.;
Kulkarni, P. S.; Marchetti, E.; LaForce, F. M.; Preziosi, M.-P.
N. Engl. J. Med. 2011, 364, 2293–2304. doi:10.1056/NEJMoa1003812
13. Kristiansen, P. A.; Diomandé, F.; Ba, A. K.; Sanou, I.;
Ouédraogo, A.-S.; Ouédraogo, R.; Sangaré, L.; Kandolo, D.; Eké, F.;
Saga, I. M.; Iark, T. A.; Misegades, L.; Martin, S. W.; Thomas, J. D.;
Tiendrebeogo, S. R.; Hassan-King, M.; Djingarey, M. H.;
Messonnier, N. E.; Préziosi, M.-P.; LaForce, F. M.; Caugant, D. A.
Clin. Infect. Dis. 2013, 56, 354–363. doi:10.1093/cid/cis892
14. Trotter, C. L.; Ramsay, M. E.; Gray, S.; Fox, A.; Kaczmarski, E.
Lancet Infect. Dis. 2006, 6, 616–617.
doi:10.1016/S1473-3099(06)70584-9
15. http://www.who.int/nuvi/meningitis/en/index.html
16. Hong, E.; Giuliani, M. M.; Deghmane, A.-E.; Comanducci, M.;
Brunelli, B.; Dull, P.; Pizza, M.; Taha, M.-K. Vaccine 2013, 31,
1113–1116. doi:10.1016/j.vaccine.2012.12.022
17. Bröker, M.; Costantino, P.; DeTora, L.; McIntosh, E. D.; Rappuoli, R.
Biologicals 2011, 39, 195–204. doi:10.1016/j.biologicals.2011.05.004
18. Micoli, F.; Romano, M. R.; Tontini, M.; Cappelletti, E.; Gavini, M.;
Proietti, D.; Rondini, S.; Swennen, E.; Santini, L.; Filippini, S.;
Balocchi, C.; Adamo, R.; Pluschke, G.; Norheim, G.; Pollard, A. J.;
Saul, A.; Rappuoli, R.; MacLennan, C. A.; Berti, F.; Costantino, P.
Proc. Natl. Acad. Sci. U. S. A. 2013, 110, 19077–19082.
doi:10.1073/pnas.1314476110
19. Bundle, D. R.; Jennings, H. R. Can. J. Biochem. 1974, 52, 723–725.
doi:10.1139/o74-102
20. Adamo, R.; Micoli, F.; Proietti, D.; Berti, F. Synth. Commun. 2014, 44,
1266–1273. doi:10.1080/00397911.2013.853189
21. Morelli, L.; Poletti, L.; Lay, L. Eur. J. Org. Chem. 2011, 5723–5777.
doi:10.1002/ejoc.201100296
22. Costantino, P.; Rappuoli, R.; Berti, F. Expert Opin. Drug Discovery
2011, 6, 1045–1067. doi:10.1517/17460441.2011.609554
23. Hsu, C.-H.; Hung, S.-C.; Wu, C.-Y.; Wong, C.-H.
Angew. Chem., Int. Ed. 2011, 50, 11872–11923.
doi:10.1002/anie.201100125
24. Hecht, M.-L.; Stallforth, P.; Varón Silva, D.; Adibekian, A.;
Seeberger, P. H. Curr. Opin. Chem. Biol. 2009, 13, 354–359.
doi:10.1016/j.cbpa.2009.05.127
25. Morelli, L.; Lay, L. ARKIVOC 2013, Part (ii), 166–184.
doi:10.3998/ark.5550190.0014.214
26. Adamo, R.; Romano, M. R.; Berti, F.; Leuzzi, R.; Tontini, M.;
Danieli, E.; Cappelletti, E.; Cakici, O. S.; Swennen, E.; Pinto, V.;
Brogioni, B.; Proietti, D.; Galeotti, C. L.; Lay, L.; Monteiro, M. A.;
Scarselli, M.; Costantino, P. ACS Chem. Biol. 2012, 7, 1420–1428.
doi:10.1021/cb300221f
27. Gao, Q.; Tontini, M.; Brogioni, G.; Nilo, A.; Filippini, S.; Harfouche, C.;
Polito, L.; Romano, M. R.; Costantino, P.; Berti, F.; Adamo, R.; Lay, L.
ACS Chem. Biol. 2013, 8, 2561–2567. doi:10.1021/cb400463u
28. Nikolaev, A. V.; Botvinko, I. V.; Ross, A. J. Carbohydr. Res. 2007, 342,
297–344. doi:10.1016/j.carres.2006.10.006
29. Guilano, R. M.; Deisenroth, T. W. J. Carbohydr. Chem. 1987, 6,
295–299. doi:10.1080/07328308708058878
30. Mason, B. P.; Price, K. E.; Steinbacher, J. L.; Bogdan, A. R.;
McQuade, D. T. Chem. Rev. 2007, 107, 2300–2318.
doi:10.1021/cr050944c
31. Geyer, K.; Gustafsson, T.; Seeberger, P. H. Synlett 2009, 2382–2391.
doi:10.1055/s-0029-1217828
32. Hartman, R. L.; McMullen, J. P.; Jensen, K. F. Angew. Chem., Int. Ed.
2011, 50, 7502–7519. doi:10.1002/anie.201004637
33. McQuade, D. T.; Seeberger, P. H. J. Org. Chem. 2013, 78, 6384–6389.
doi:10.1021/jo400583m
34. Nikolaev, A. V.; Rutherford, T. J.; Ferguson, M. A. J.;
Brimacombe, J. S. J. Chem. Soc., Perkin Trans. 1 1995, 1977–1987.
doi:10.1039/P19950001977
35. Thijssen, M.-J. L.; Hales, K. M.; Kamerling, J. P.; Vliegenthart, J. F. G.
Bioorg. Med. Chem. 1994, 2, 1309–1317.
doi:10.1016/S0968-0896(00)82081-7
36. Gao, Q.; Zaccaria, C.; Tontini, M.; Poletti, L.; Costantino, P.; Lay, L.
Org. Biomol. Chem. 2012, 10, 6673–6681. doi:10.1039/c2ob25222h
37. Bardotti, A.; Averani, G.; Berti, F.; Berti, S.; Carinci, V.; D’Ascenzi, S.;
Fabbri, B.; Giannini, S.; Giannozzi, A.; Magagnoli, C.; Proietti, D.;
Norelli, F.; Rappuoli, R.; Ricci, S.; Costantino, P. Vaccine 2008, 26,
2284–2296. doi:10.1016/j.vaccine.2008.01.022
38. Vecchi, S.; Bufali, S.; Skibinski, D. A. G.; O’Hagan, D. T.; Singh, M.
J. Pharm. Sci. 2012, 101, 17–20. doi:10.1002/jps.22759
39. Giuliani, M. M.; Santini, L.; Brunelli, B.; Biolchi, A.; Arico, B.;
Di Marcello, F.; Cartocci, E.; Comanducci, M.; Masignani, V.; Lozzi, L.;
Savino, S.; Scarselli, M.; Rappuoli, R.; Pizza, M. Infect. Immun. 2005,
73, 1151–1160. doi:10.1128/IAI.73.2.1151-1160.2005
40. Andrews, N.; Borrow, R.; Miller, E. Clin. Diagn. Lab. Immunol. 2003,
10, 780–786. doi:10.1128/CDLI.10.5.780-786.2003
41. Hirve, S.; Bavdekar, A.; Pandit, A.; Juvekar, S.; Patil, M.;
Preziosi, M.-P.; Tang, Y.; Marchetti, E.; Martellet, L.; Findlow, H.;
Elie, C.; Parulekar, V.; Plikaytis, B.; Borrow, R.; Carlone, G.;
Kulkarni, P. S.; Goel, A.; Suresh, K.; Beri, S.; Kapre, S.; Jadhav, S.;
Preaud, J.-M.; Viviani, S.; LaForce, F. M. Vaccine 2012, 30,
6456–6460. doi:10.1016/j.vaccine.2012.08.004
42. Poszgay, V.; Chu, C.; Pannell, L.; Wolfe, J.; Robbins, J. B.;
Schneerson, R. Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 5194–5197.
doi:10.1073/pnas.96.9.5194
Beilstein J. Org. Chem. 2014, 10, 2367–2376.
2376
43. Mawas, F.; Niggemann, J.; Jones, C.; Corbel, M. J.; Kamerling, J. P.;
Vliegenthart, J. F. G. Infect. Immun. 2002, 5107–5114.
doi:10.1128/IAI.70.9.5107-5114.2002
License and Terms
This is an Open Access article under the terms of the
Creative Commons Attribution License
(http://creativecommons.org/licenses/by/2.0), which
permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
The license is subject to the Beilstein Journal of Organic
Chemistry terms and conditions:
(http://www.beilstein-journals.org/bjoc)
The definitive version of this article is the electronic one
which can be found at:
doi:10.3762/bjoc.10.247
